News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) HIV Drug Strategy Seen Shielding Patent


3/21/2014 7:35:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck & Co. (MRK) is set to sell an HIV medication in India by mid-year in partnership with local company Cipla Ltd. (CIPLA), a strategy that may help the U.S. drugmaker protect its patent as the Asian nation seeks cheaper generics. The price of the co-marketed product will be announced in about three months, according to Cipla’s Chief Medical Officer Jaideep Gogtay. The therapy, sold under the brand Isentress, is among more than 20 that an Indian government panel was preparing to assess for compulsory licenses, which allow cheaper local copies without the patent owner’s consent.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES